SoftBank Group Corp. is in talks to invest as much as another $30 billion in Sam Altman's OpenAI, according to a report by The Wall Street Journal, citing people familiar with the knowledge of the matter. ...

Core Insights - Western New England Bancorp (WNEB) reported $22 million in revenue for the quarter ended December 2025, marking an 18.7% year-over-year increase and exceeding the Zacks Consensus Estimate of $21.8 million by 0.95% [1] - The company achieved an EPS of $0.26, up from $0.16 a year ago, resulting in an EPS surprise of 23.81% compared to the consensus estimate of $0.21 [1] Financial Performance Metrics - Net Interest Margin was reported at 2.9%, matching the average estimate from two analysts [4] - The Efficiency Ratio was 72.1%, slightly better than the average estimate of 72.9% from two analysts [4] - Total Non-Interest Income was $3.17 million, slightly above the average estimate of $3.16 million [4] - Net Interest Income stood at $18.83 million, exceeding the average estimate of $18.64 million [4] Stock Performance - Shares of Western New England Bancorp have returned +0.9% over the past month, outperforming the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Attention is focused on whether the Indian markets are under pressure across assets, with stocks, the rupee and bonds all weakening, leaving investors banking on the budget to reset sentiment. Equities are down about 4% this year, with the NSE Nifty 50 Index off to the worst start to a year since 2016. Global funds remain net sellers of shares, while heavy bond issuance continues to weigh on debt markets. Local stocks have wiped out around $360 billion in market value so far this month, according to data c ...

Core Viewpoint - Altimmune, Inc. has entered into a securities purchase agreement for the sale of 17,045,454 shares of common stock, expected to generate approximately $75 million in gross proceeds, to fund its Phase 3 trial for pemvidutide and for general corporate purposes [1][2]. Group 1: Offering Details - The offering involves 17,045,454 shares of common stock or pre-funded warrants, with gross proceeds anticipated to be around $75 million before expenses [1]. - The offering is expected to close on or about January 29, 2026, pending customary closing conditions [1]. - Titan Partners is acting as the sole placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to prepare for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes [2]. - Pemvidutide is a dual agonist targeting glucagon and GLP-1 receptors, showing potential as a differentiated therapy for MASH, supported by recent Phase 2b data and Breakthrough Therapy Designation from the U.S. FDA [2]. Group 3: Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on therapies for serious liver diseases, with pemvidutide as its lead candidate [6]. - The company aims to deliver significant patient impact and long-term shareholder value through its innovative therapies [2].

Gold steadied after seven days of gains, with traders digesting a record-breaking rally fueled by US dollar weakness and a flight from sovereign bonds and currencies. Bullion was near $5,160 an ounce, having risen 3.4% on Tuesday - its biggest one-day gain since April. President Donald Trump said he was not concerned about a drop in the value of the dollar that has dragged the world's premier reserve currency to its weakest level in nearly four years.That decline, combined with heightened geopolitical risks ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Texas Governor Greg Abbott on Tuesday (local time) ordered a freeze on H-1B visas for highly skilled workers in state agencies and universities, calling for jobs to go to qualified Texans instead of immigrants. He also announced a ban on China-linked firms from state systems."Texans come first," wrote Abbott on X, making the announcement."I’m directing state agencies and universities to freeze new H-1B visa petitions. Texas taxpayers invest billions to train our workforce. Those jobs should go to Texans," h ...

Group 1 - C3.AI is in discussions to merge with Automation Anywhere, a privately held startup specializing in automation software [1] - The report comes from The Information, citing sources familiar with the negotiations [1] - This potential merger highlights the growing interest in enterprise artificial intelligence and automation solutions [1]

Core Insights - Applied Digital has experienced significant stock growth, with a nearly 540% increase over the past 12 months, driven by rapid growth and new leases [1] - The company plans to spin off its unprofitable cloud-based AI infrastructure platform, which is seen as a competitor to its own customers [2] - Equinix is presented as a more stable investment option for long-term income investors, offering reliable dividends and stable profits [7] Applied Digital Overview - From fiscal 2022 to fiscal 2025, Applied Digital's revenue increased from $8.5 million to $144.2 million, excluding its cloud business [3] - The company has secured $16 billion in lease payments over the next 15 years, primarily from CoreWeave [3] - Despite expansion efforts, analysts predict Applied Digital will remain unprofitable post-spin-off of its cloud business [4] Equinix Overview - Equinix operates over 270 data centers with a total capacity of approximately 1 GW, making it one of the largest data center REITs [8] - The company serves over 10,000 customers and generates significantly more revenue than Applied Digital, with a gross margin of 30.89% [9][10] - Equinix has consistently raised its dividend payout since becoming an REIT, currently offering a forward dividend yield of 2.3% [11] Financial Performance - Equinix's revenue and EPS grew at CAGRs of 10% and 19% from 2020 to 2024, with expectations for continued growth [11][13] - For 2025, Equinix anticipates an adjusted funds from operations (AFFO) per share increase of 8%-11%, easily covering its dividend rate [12] - Analysts project revenue and EPS growth of 6% and 74%, respectively, for the current year, with further growth expected from 2025 to 2027 [13]

Core Insights - W.R. Berkley Corporation (WRB) is a significant player in the property and casualty insurance sector, with a current stock price of $67.09 and a price target set by Truist Financial at $80, indicating a potential upside of 19.24% [1][6] Financial Performance - WRB reported a quarterly earnings per share (EPS) of $1.13, slightly below the Zacks Consensus Estimate of $1.14, reflecting a minor earnings surprise of -0.59% [2][6] - The company generated $3.72 billion in revenue for the quarter ending December 2025, which was 0.94% below the Zacks Consensus Estimate but represents an increase from $3.51 billion in the same quarter the previous year [3][6] Stock Performance - The current stock price of WRB is $67.24, showing a modest increase of 0.54% from the previous day, with fluctuations between $65.29 and $69.22 during the trading day [4] - Over the past year, WRB's stock has experienced a high of $78.96 and a low of $58.07, indicating volatility in its stock price [4] Market Position - WRB has a market capitalization of approximately $25.55 billion, highlighting its significance in the insurance industry [5] - The trading volume for WRB today is 3,305,185 shares, indicating active investor interest [5]